Numerous drugs across multiple drug classes are available for the treatment of MDD. Yet current therapies are not sufficiently effective in all patients, and those patients with TRD have become the target of drug development. Furthermore, the treatment armamentarium is growing increasingly genericized, which has improved patient access to antidepressants as well as eased restrictions on off-label adjunctive use of atypical antipsychotics. At the same time, the expanding generics presence has given payers greater leverage to control drug-treatment costs in MDD. Understanding the current and expected influence of clinical metrics and value for dollar on market access and medical practice are key for developers of new therapies for MDD.
- What factors influence physician prescribing of select therapies for MDD? Which therapies are succeeding and which are stumbling based on these factors?
- In this mature and highly genericized treatment landscape, what actions can marketers of therapies used to treat MDD employ to attain successful market access and thus overall sales?
- How are MCOs performing value assessments for MDD therapies, and what are the preferred pharmacoeconomic models?
- To which of their MDD patients do physicians anticipate prescribing the emerging therapies ALKS-5461 (Alkermes), esketamine (Janssen), and rapastinel (Allergan)? How do payers expect to reimburse these therapies?
Access & Reimbursement: Provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so you can build your market access strategy and optimize your brand positioning.